Purified mouse nerve growth factor (NGF) radiolabeled with 125 was tested for its ability to bind to a variety of different cultured cells. NGF A 36-year-old woman underwent wide excision of an irregular, black, elevated mole at the left scapular area. Pathological examination revealed invasive, malignant melanoma. The patient was re-admitted several months later for excisional biopsy of recurrent melanoma at the left side of the jaw. At that time, left axillary adenopathy was noted; of 20 nodes excised, one was positive for metastatic melanoma. During the following 2' years the patient received radiation therapy to the cranial vault as well as chemotherapy for systemic melanoma. However, a space-occupying lesion developed deep in the right frontal lobe and metastatic melanoma was excised. Part of this tumor was sent to our laboratory for initiation of the A875 line. The pathological report on this specimen indicated a 5 X 3.3 X 0.3 cm mass, containing numerous mitotic figures, giant cells, and pleomorphic cells containing dark brown melanin granules. After a progressively deteriorating course, the patient expired 6 months after surgery.
Nerve growth factor (NGF) (1) binds to specific membrane receptors on the surface of relatively few cell types in culture. It will stimulate the outgrowth of axons from sympathetic ganglia, providing the basis for an assay of its biologic activity (2). Mouse neuroblastoma cells in culture have also been reported to have specific NGF binding sites (3) . In this study we show that the great majority of cultured cells (fibroblasts and epithelial cells from various species, and normal as well as tumor cells) have no detectable NGF receptors. In striking contrast, human and hamster melanoma cells have abundant NGF receptors. The availability of continuous cell lines with large numbers of high affinity NGF receptors has made it possible to develop a competition binding assay that readily detects 0.1 biologic unit (1 ng) of NGF.
MATERIALS AND METHODS Cells. The majority of the human tumor lines tested, including five of the six melapomas, were developed in this laboratory; two of them (A375 and A875) have been described previously (4) . Melanoma line Hs294 was obtained from the Naval Biological Research Laboratory, Oakland, Calif., as was the embryonic fibroblast line HsO161 (AA422). Several of the nonhuman cell lines were obtained from the American Type Culture Collection. The pertinent clinical and cell culture history on the line chosen for detailed study in this report, A875, is as follows:
A 36-year-old woman underwent wide excision of an irregular, black, elevated mole at the left scapular area. Pathological examination revealed invasive, malignant melanoma. The patient was re-admitted several months later for excisional biopsy of recurrent melanoma at the left side of the jaw. At that time, left axillary adenopathy was noted; of 20 nodes excised, one was positive for metastatic melanoma. During the following 2' years the patient received radiation therapy to the cranial vault as well as chemotherapy for systemic melanoma. However, a space-occupying lesion developed deep in the right frontal lobe and metastatic melanoma was excised. Part of this tumor was sent to our laboratory for initiation of the A875 line. The pathological report on this specimen indicated a 5 X 3.3 X 0.3 cm mass, containing numerous mitotic figures, giant cells, and pleomorphic cells containing dark brown melanin granules. After a progressively deteriorating course, the patient expired 6 months after surgery.
The A875 cells grew rapidly in primary culture with a mass doubling time of approximately 4 days on early passages. The cells grow in soft agar, on monolayers of normal cells, and are tumorigenic in nude mice. In culture they contain abundant intracytoplasmic pigment granules. Frozen samples are available from the fourth through sixty-fifth passages. The experiments presented in this paper were done with cultures at passage 20 (Fig. 4) . The T1/2 for dissociation at 4°was determined to be 110 min, a value comparable to that obtained using homogenates of a sympathetic ganglion microsomal fraction (17) . No dilution dependency could be found over a 10-fold range for the dissociation of bound 125I-NGF from the A875 cells.
The relatively large number (6.9 X 105 per cell) of high affinity NGF receptors on A875 cells has made it possible to develop a sensitive, specific, and rapid competitive binding assay capable of measuring NGF. Fig. 5 shows the results of a competitive binding assay for NGF. In the assay shown, 50% of the maximal competition was seen with 1.5 ng of NGF, while 15% inhibition required 0.25 ng of NGF. The latter figure corresponds to 0.025 biologic unit (BU) of activity. In contrast, 5 Mg of EGF in the same experiment showed no detectable competition for NGF binding sites. The sensitivity of the assay could be further increased by using still fewer target cells and/or by increasing the specific activity of the radiolabeled NGF.
Human melanoma A875 cells were seeded into microtiter wells at 2 X 104 cells per well in serum-depleted medium (19) supplemented with various concentrations of NGF ranging from 24 pg to 15 ng. Two other human cell cultures lacking detectable NGF receptors, a normal second trimester embryo cell strain (HsOI61) and a human fibrosarcoma (HT1080), were similarly tested. Only in the case of the A875 cells could a survival enhancing effect be seen. The 2 X 104 cells per well seeded NGF BOUND (ng) FIG. 3 . Cultures of A875 were grown to a density of 4 X 106 cells per 60-mm petri dish. After cells were washed twice with binding buffer, 20 ng of 1251-NGF (170,000 cpm) mixed with various known amounts of cold NGF were added to the dishes in 1.5 ml of binding buffer. These known amounts included a range from 1.5 ng to 4.5 ug. After a 60-min incubation at room temperature, the dishes were washed and cells were lysed as described. The ratio of bound/free 1251-NGF was determined and plotted as a function of the ng of NGF bound (15) . 
